reports
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-Hi...
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026 GARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), today announced being selected to present an abstract featuring data from the Phase 1 trial of intratumoral UNO in solid tumor metastases at the American A...
BCB Bancorp, Inc. Reports Net Loss of $12.0 Million in Fourth Quarter ...
BCB Bancorp, Inc. Reports Net Loss of $12.0 Million in Fourth Quarter 2025 BAYONNE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), today reported a net loss of $12.0 million for the fourth quarter of 2025, compared to net income of $4.3 million in the third quarter of 2025, and net income of $3.3 million for the fourth quarter of 2024. The Company’s loss per diluted share for the fourth quarter was ($0.73) compared to earnings per diluted share of $0.22 in the preceding quarter and $0.16 i...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferen...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that Steve Lisi, Chairman & Chief Executive Officer of Beyond Air, will participate in the 13th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 9th to 11th in Snowbird, UT and the Noble Cap...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PKG PACKAGING CORPORATION OF AMERICA
SCCO SOUTHERN COPPER CORPORATION
PAA PLAINS ALL AMERICAN PIPELINE L.P.
LXU LSB INDUSTRIES INC.
LNTH LANTHEUS HOLDINGS INC
KMB KIMBERLY-CLARK CORPORATION
JYNT JOINT CORP
HUBB HUBBELL INCORPORATED CLASS B
HRL HORMEL FOODS CORPORATION
GPRK GEOPARK
DAN DANA INCORPORATED
CVS CVS HEALTH CORPORATION
BLL BALL CORPORATION
ASH ASHLAND GLOBAL HOLDINGS INC.
ACD ADECOAGRO S.A.
ADM ARCHER-DANIELS-MIDLAND COMPANY
NYT NEW YORK TIMES COMPANY CLASS A
ATRO ASTRONICS CORPORATION
DRI DARDEN RESTAURANTS INC.
SXC SUNCOKE ENERGY INC.
CDZI CADIZ INC.
TEC TECHNIPFMC PLC
RNGR RANGER ENERGY SERVICES
CSTL CASTLE BIOSCIENCES
APA APA CORPORATION
AKLCP ONTO INNOVATION INC.
PR KOLTSOVO AIRPORT
BG PERMIAN RESOURCES CORPORATION
PRMB BUNGE LIMITED
USAU PRIMO BRANDS CORP
UAN US GOLD CORP
DFTX ARCADIAN PARTNERS LP PFD
VXX DEFINIUM THERAPEUTICS INC.
IPATH SERIES B S&P 500 VIX SHORT-TERM FUTURES ETN
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Confe...
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its third fiscal quarter ended December 31, 2025 on Friday, February 13, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am East...
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c...
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to one (1) new non-executive employee in the aggregate amount of 36,118 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of January 14, 2026, as an i...
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Mark...
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules GARDEN CITY, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that it entered into a securities purchase agreement with an institutional investor to issue and sell, in a private placement priced at-the-market under Nasdaq rules, 3,930,818 shares of common stock (or pre-funded warrants...
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNO...
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majorit...
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manus...
InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC) The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company’s C-GUARDIANS pivotal trial have now been published in ...
Beyond Air® Appoints Dan Moorhead as Chief Financial Officer
Beyond Air® Appoints Dan Moorhead as Chief Financial Officer GARDEN CITY, N.Y., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the appointment of Dan Moorhead as Chief Financial Officer, effective January 5, 2026. Duke Dewrell, the Company's Controller, who had assumed CFO responsibilities at the Company on an interim basis in November 2025, will resume his prior role as of...
Beyond Air® Signs New International LungFit PH® Distribution Agreement...
Beyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and Brazil Distribution network coverage expanded to a total of 39 countries GARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the recent signing of several key international distribution agreements for LungFit® PH, expanding its network to include Germany, Bra...
Beyond Air® Announces Transition of Chief Financial Officer
Beyond Air® Announces Transition of Chief Financial Officer Launched search for permanent successor GARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Doug Larson has resigned as Chief Financial Officer to pursue another opportunity. Mr. Larson will continue to serve as CFO through December 5, 2025, at which time the CFO responsibilities at the Company...
Landmark CREST-2 Study Published in the New England Journal of Medicin...
Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis MIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, welcomes the recent presentation and publication of CREST-2 data which demonstrated p...
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c...
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to eight (8) new non-executive employees in the aggregate amount of 122,054 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of November 20, 2025, as...
InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthc...
InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to participate in a fireside discussion at the upcoming Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd at 12:30 pm Eastern Time (ET). A live audio webcast and replay of the discussion may be accessed on the “Investor Calendar” section of the company’s website at: About InspireMD, Inc.InspireMD seeks t...
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and P...
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025 Achieves certificate for Medical Device Single Audit Program (MDSAP) Updated fiscal year 2026 revenue guidance to $8 – $10 million Conference call at 4:30 p.m. ET today, November 10th GARDEN CI...
Beyond Air® Secures Up to $32 Million to Accelerate Growth
Beyond Air® Secures Up to $32 Million to Accelerate Growth Enters agreements for a $12 million promissory note and a $20 million equity line of credit with Streeterville Capital Proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025, including $12 million from the promissory note Extends cash runway into calendar 2027 GARDEN CITY, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the p...
InspireMD Reports Third Quarter 2025 Financial Results
InspireMD Reports Third Quarter 2025 Financial Results Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the third quarter and nine months ended September 30, 2025. Recent Business Highlights: Initiated U.S. commercial launch of the CGuard Prime carotid stent systemCompleted over 100 U.S. carotid procedures across ...
InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer
InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention. “We are thrilled to have Dr. Soukas join InspireMD to help lead our clinical and medical organization with strategy and oversight at this pivotal time for the Company,” said Marvin ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.